Tritonix.ai

News / Taiwan / economic_daily

Taiwan Biotech Firms Joyful: Fortune and PharmaEssentia Report Record August Revenues

Health Technology · Biotechnology · economic_daily · 2026-09-08

Taiwanese biotech companies Fortune and PharmaEssentia posted record-breaking August revenues, driven by strong product sales and international market expansion.

What Happened

Fortune's Revenue Growth: Fortune reported an August revenue of NT$754 million, a nearly 50% year-over-year increase, marking a new record for the period. The growth was primarily fueled by robust sales in oncology, cardiovascular, and women's health products.

PharmaEssentia's Record Performance: PharmaEssentia achieved a record monthly revenue of NT$2.617 billion in August, representing a 105.4% year-over-year surge. This performance was bolstered by strong sales in the U.S. market and the steady distribution of its Ropeg injection pens.

Fortune's Global Expansion: Fortune is deepening its footprint in Asia, having recently secured distribution partnerships in Vietnam for products expected to launch in 2029. Additionally, the company's hormone facility passed a Japanese PMDA inspection, paving the way for future international market entry.

PharmaEssentia's Regulatory Milestones: PharmaEssentia's blood cancer drug Ropeg recently received approval for Essential Thrombocythemia (ET) in both Japan and the U.S. The company expects to benefit from a seven-year market exclusivity period in the U.S., significantly enhancing its long-term growth outlook.

Read original

More in Health Technology

Xufu August Revenue Soars 187.52% Year-over-Year

Health Technology · cnyes · 2026-09-08

Xufu (4119) reported August 2026 revenue of NT$149 million, a 187.52% year-over-year surge, with year-to-date revenue growth at 14.21%.

4119

AstraZeneca Reports Positive Late-Stage Data for Tozorakimab in COPD Treatment

Health Technology · cnbc · 2026-09-08

AstraZeneca's experimental COPD drug, tozorakimab, showed significant efficacy in late-stage trials, bolstering the company's multi-billion dollar sales outlook.

AZN, AZN, SNY, GSK, GILD, SNY, REGN, GSK, IBB

Lumosa Therapeutics August Revenue Skyrockets Over 5000% YoY

Health Technology · cnyes · 2026-09-08

Lumosa Therapeutics (6535) reported a massive 5,135.84% year-over-year revenue surge in August, with the stock outperforming the biotech sector index.

6535

Latest in Taiwan

Chang Hwa Bank Reports Record 8-Month Profit Growth of 23.21%

Finance · cnyes · 2026-09-08

Chang Hwa Bank announced an 8-month net profit of NT$15.57 billion, driven by strong lending and wealth management performance, resulting in an EPS of NT$1.29.

2801

Fuchang's August Revenue Hits Second-Highest Monthly Record

Process Industries · economic_daily · 2026-09-08

Fuchang-KY reported August revenue of NT$1.192 billion, marking a 42.4% year-on-year increase, driven by strong seasonal demand and holiday restocking.

8411

Taiwan Mobile Eyes Top Telecom Spot with Potential SYSTEX Acquisition

Technology Services · cnyes · 2026-09-08

Taiwan Mobile CEO Jamie Lin says a successful acquisition of SYSTEX could propel the company's revenue to challenge the industry leader by next year.

2412, 3045, 6214

Junxing-KY Posts Record Eight-Month Revenue, Eyes Robotics Growth

Producer Manufacturing · economic_daily · 2026-09-08

Junxing-KY reported record cumulative revenue of NT$2.125 billion for the first eight months, bolstered by strong demand for robotics and smart transmission.

4571